, /PRNewswire/ -- The global gonorrhea therapeutics market size is estimated to grow by from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 5.55% during the forecast period.
For comprehensive forecast and historic data on regions, market segments, customer landscape, and companies- The global gonorrhea therapeutics market is experiencing growth due to increased funding from the US government through the CDC for combating antibiotic resistance. Four of nine regional public health laboratories are dedicated to gonorrhea-related testing and genomic sequencing, identifying antibiotic-resistant strains and providing appropriate treatment. The CDC's SURRG program aims to enhance surveillance, build diagnostic facilities, and prevent the spread of antibiotic-resistant gonorrhea strains.
This control of resistance will boost patient adherence to antibiotic therapy, positively impacting market growth. The gonorrhea market for therapeutics is currently experiencing significant trends. Drugs such as Ceftriaxone and Azithromycin are commonly used for treatment.
Resistance is a growing concern, with strains becoming more difficult to treat. Dual therapy, combining an injectable antibiotic with an oral one, is becoming more popular to combat resistance. Infected individuals should seek medical attention promptly to prevent complications.
The need for new and effective treatments continues to drive research and development in this field. Infecions can.
